Nexus Pharmaceuticals, a leading sterile manufacturer in the pharmaceutical industry, announced that its pharmaceutical manufacturing facility in Pleasant Prairie, Wisconsin, was successfully inspected by the Food and Drug Administration (FDA), which will allow Nexus to begin commercial operations. 

The Pleasant Prairie facility, which spans more than 84,000 square feet, is equipped with state-of-the-art isolator technology and adheres to the highest current good manufacturing practice (CGMP) standards. The facility will produce a wide array of injectable medications, providing hospitals and clinicians access to safe, affordable, and critical-need medications.

"We are thrilled to receive the EIR for our Pleasant Prairie facility," said Usman Ahmed, President & Chief Executive Officer of Nexus Pharmaceuticals. "This is a major milestone for our company and reflects our commitments to reshoring sterile pharmaceutical manufacturing to the US Looking ahead, we are now in an even stronger position to accelerate growth and drive innovation in our industry.”

The rigorous FDA approval process ensures that facilities meet strict safety and quality standards. Nexus Pharmaceuticals plans to manufacture several NDAs and ANDAs from the Wisconsin-based facility to bring innovative products as well as supply chain durability to the US healthcare system. The leadership, regulatory, and business functions will remain in the Illinois headquarters facility.

Ahmed continued, "We are proud of our team's hard work and focus on achieving a successful inspection. This accomplishment is a testament to the expertise and dedication of our employees and our commitment to providing the highest quality medication to our customers."